雌激素受体连接体结合域四重化通过一个明确的完整的雌激素受体对手的Allosteric诱导
Emma C Fink1, Reena Chawla2, Govinda R Hancock1
1Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois 60546, United States.
ACS medicinal chemistry letters
|February 18, 2026
概括
新的研究引入了OP-1690,一种用于ER+乳腺癌的全新雌激素受体对抗剂 (CERAN). 这种化合物独特地形成了ERα四次体,提供了超越传统治疗的新治疗途径.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药用化学 医学化学
背景情况:
- 完整的雌激素受体对抗剂 (CERAN) 对于治疗晚期雌激素受体阳性 (ER+) 乳腺癌至关重要.
- 现有的CERAN化学支架限制了对雌激素受体 (ER) 药理学的探索.
研究的目的:
- 综合和描述一个具有独特,不受约束的核心的新CERAN.
- 为了研究新化合物的独特作用机制,OP-1690.
主要方法:
- 对OP-1690 (化合物2) 的合成.
- 结构和生物物理分析以确定受体相互作用.
- 评估雌激素受体α (ERα) 连接体结合域 (LBD) 的形成.
主要成果:
- OP-1690 (2) 已成功合成,具有新的不受约束的核心.
- 化合物2独特地诱导ERα LBD四分体的形成.
- 这种四聚体形成代表了一种超出传统ERα同极化机制.
结论:
- 像OP-1690这样的新型CERAN支架可以揭示以前未知的ER作用机制.
- OP-1690促进ERα四聚体形成的能力为ER药理学提供了新的见解.
- 这一发现可能会导致改善ER+乳腺癌的治疗策略.
相关概念视频
The Two-State Receptor Model
3.1K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.1K
Drug-Receptor Interaction: Antagonist
5.2K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.2K
Drug-Receptor Interactions
7.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.7K
Cooperative Allosteric Transitions
9.0K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.0K
Cooperative Allosteric Transitions
2.7K
2.7K
Drug-Receptor Interaction: Agonist
4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K


